Bakshi Chetana, Amare Kadam Pratibha, Abhyankar Dhiraj, Baisane Chanda, Banavali Shripad, Advani Suresh
Cancer Cytogenetics Laboratory, Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Indian J Pediatr. 2003 Sep;70(9):755-8. doi: 10.1007/BF02724321.
The incidence of acute leukemia in children with Down syndrome (DS) is high as compared to general population. Recent findings have demonstrated that DS children with acute myeloid leukemia (AML) have the highest event free survival rates with high dose cytosine arabinoside (Ara-C). We present 3 year-old DS female child with AML-M5, whose chromosomal analysis revealed constitutional t(21;21) alongwith del(5)(q31q33) and a unique translocation t(16;20)(q13;q12). After chemotherapy, child achieved complete clinical remission. Karyotype analysis of remission marrow showed disappearance of abnormal clone of der(20) t(16;20)(q13;q12), del(5q) indicating cytogenetic remission too. This case alongwith supportive literature indicate that pediatric DS-AML is a distinct biologic sub-group differs from that of non-DS-AML with respect to chemosensitivity.
与普通人群相比,唐氏综合征(DS)患儿急性白血病的发病率较高。最近的研究结果表明,患有急性髓性白血病(AML)的DS患儿采用高剂量阿糖胞苷(Ara-C)治疗时无事件生存率最高。我们报告了一名3岁患有AML-M5的DS女童,其染色体分析显示存在先天性t(21;21)以及del(5)(q31q33)和一种独特的易位t(16;20)(q13;q12)。化疗后,患儿实现了完全临床缓解。缓解期骨髓的核型分析显示,der(20) t(16;20)(q13;q12)、del(5q)的异常克隆消失,表明也实现了细胞遗传学缓解。该病例以及相关文献表明,小儿DS-AML是一个独特的生物学亚组,在化疗敏感性方面与非DS-AML不同。